Navigation Links
EUCODIS Bioscience Appoints Bhupinder Hundle to Senior Vice President Marketing & Sales
Date:10/12/2009

VIENNA, Austria, October 12 /PRNewswire/ -- EUCODIS Bioscience, a company developing, customizing, manufacturing, and marketing enzymes for the chemical industry, announced today that it has appointed Bhupinder Hundle, PhD, to the newly created position of Senior Vice President Marketing & Sales. Dr. Hundle will be responsible for the worldwide sales of EUCODIS Bioscience' products. In 2009 the Company has started bringing to market its own enzymes portfolio. The Company had previously established its technology and its enzyme development expertise in commercial collaborations with industry partners.

"We are excited about the wealth of experience that Bhupinder brings on board in establishing and leading an effective sales force", said Rudy Pandjaitan, PhD, CEO of EUCODIS Bioscience. "At EUCODIS Bioscience Bhupinder will be responsible for building the sales structure that optimally serves our target industries in Europe, the US, and Asia."

"I am proud to join a biotechnology company like EUCODIS Bioscience, with its proven capabilities in developing and bringing industrial enzymes to the market", commented Dr. Bhupinder Hundle. "With its industry experience and its powerful technology, EUCODIS Bioscience has the potential to become a key enabler of white biotechnology applications, both in established industries and in future technologies such as the generation of fine chemicals from biomass."

Dr. Hundle comes to EUCODIS Bioscience from Lonza, Switzerland, where he headed the sales team for the Lonza Cell Discovery product range in UK, Ireland, the Netherlands, and Northern Europe. Prior to joining Lonza Bhupinder served as European Sales Director for Amaxa AG for 6 years. He has more than 10 years of experience in working with B2B customers in the pharmaceutical and biotechnology industries in Europe and the US.

Dr. Hundle has a B.Sc. (Hons) degree in Molecular Biology, an M.Sc. degree in Medicinal Chemistry from Loughborough University, UK, and received his PhD degree in Biochemistry from Simon Fraser University, British Columbia, Canada. He worked as a postdoctoral fellow at Chemical Biodynamics Laboratory, Chemistry Department, University of California, Berkeley and as a Senior Research Fellow at University of California, San Francisco.

About EUCODIS Bioscience

EUCODIS Bioscience GmbH develops, customizes, manufactures, and markets industrial enzymes.

EUCODIS Bioscience' products help customers in the chemical, pharmaceutical, and food and feed industries to make manufacturing processes more efficient and cleaner, and to generate products with superior properties.

EUCODIS Bioscience originally focused on developing enzymes for industrial partners, including GlaxoSmithKline, Henkel, and Lohmann Animal Health. Since 2009, the Company also markets its own products.

Led by an experienced management team, EUCODIS Bioscience is backed by Austrian and German institutional venture capital funds, founders, and private investors. The Company is headquartered in Austria, Europe, with subsidiaries in France and Germany.

    For more information, please visit http://www.eucodisbioscience.com

    Company contact EUCODIS Bioscience:
    Rudy Pandjaitan, PhD
    CEO
    EUCODIS Bioscience
    Campus Vienna Biocenter II
    Viehmarktgasse 2 a/ 2 OG
    A-1030 Vienna
    AUSTRIA
    +43-1-8900804
    office@eucodisbioscience.com

    Media contact EUCODIS Bioscience:
    Frank Butschbacher
    Investor Relations & Communications
    http://www.butschbacher.net
    +43-650-7844940
    office@butschbacher.net

SOURCE EUCODIS Bioscience


'/>"/>
SOURCE EUCODIS Bioscience
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. EUCODIS Bioscience Achieves Development Milestone in Second Collaboration With Lohmann Animal Health
2. Sangamo BioSciences Announces Research Collaboration With UCLA in Human Stem Cells Selected to Receive Clinical Research Award
3. Sangamo BioSciences Announces Plans to Initiate a Second Clinical Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS
4. Signum Biosciences Awarded Phase II SBIR Grant by the NIH for the Treatment of Rosacea
5. Regado Biosciences Releases Positive Phase 2a Data for the Reversible Anticoagulant System REG1 at the European Society of Cardiology Congress In Barcelona, Spain
6. Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech
7. Neurocrine Biosciences Presents Elagolix Data
8. Chipscreen and HUYA Bioscience to Present Clinical Data on Novel HDAC Inhibitor at the 2009 ASCO Annual Meeting
9. CMC ICOS Biologics and Implicit Bioscience Ltd Announce IC14 Antibody Manufacturing Agreement and Patent License
10. SAFC Biosciences(R) and Vivalis Collaborate to Optimize Cell Culture Media for Vaccines Production
11. ImQuest BioSciences Receives Phase I SBIR Grant to Develop a Novel Hepatitis C Virus Therapeutic Agent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... SILVER SPRING, Md. , Jan. 19, 2017 ... for the treatment of Chronic Idiopathic Constipation (CIC) in adult ... patients suffering from chronic gastrointestinal disorders," said Julie Beitz ... in the FDA,s Center for Drug Evaluation and Research. "With ... select the most appropriate treatment for their condition." ...
(Date:1/19/2017)... 19, 2017 Report Details ... Alzheimer,s Disease ... Companies – our new study reveals trends, R&D progress, ... events affecting the Alzheimer,s disease therapeutics and diagnostics market. ... key questions: - How is the Alzheimer,s disease therapeutics ...
(Date:1/19/2017)... , Jan. 19, 2017 Many patients ... for their medication when a pharmacy just a few ... prescription.  To alleviate this problem Medicationdiscountcard.com has ... to see exactly how much their medication will cost ... Made Easy Medicationdiscountcard.com ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... 2017 , ... Michael and Betsy Brauser celebrated 5 years of Betsy’s participation ... trial has been life-saving as she has been on the trial for more ... diagnosed with ovarian cancer in 2009. She underwent standard chemotherapy but a year later ...
(Date:1/20/2017)... , ... January 20, 2017 , ... ... and its sugar-free alternative VW+ 002. The drinks have been produced in collaboration ... conditions to perform during your workout. , After a successful launch in Sweden ...
(Date:1/20/2017)... ... January 20, 2017 , ... “The Angel”: a heartwarming ... set out for each of his children. “The Angel” is the creation of published ... in New York City, and impassioned writer. , When asked of her new book, ...
(Date:1/20/2017)... ... , ... “I Forgive You”: a fine examination of how God handles sin, including how ... published author, Stephen Miller, who, for over ten long years has been waiting to release ... Trinidad and Tobago, he has been serving the Lord for over twenty years, and he ...
(Date:1/20/2017)... ... ... “Christmas in Suffolk”: a story of love, secrets, and mystery. “Christmas in Suffolk” ... she works in a daycare and looks for inspiration in the local coffee shop ... Sara Seymour’s new book is an adventure of love and secrets. , ...
Breaking Medicine News(10 mins):